NeuroSense (NRSN) CFO awarded 200,000 restricted shares vesting over 2 years

Rhea-AI Filing Summary

Eisenberg Or reported acquisition or exercise transactions in this Form 4 filing.

NeuroSense Therapeutics Ltd. Chief Financial Officer Eisenberg Or received a grant of 200,000 restricted Ordinary Shares as equity compensation. The shares were granted at $0.00 per share and will vest in equal quarterly installments over a two-year period starting on March 26, 2026, provided he continues to serve the company on each vesting date. Following this award, he directly holds 1,254,050 Ordinary Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Eisenberg Or

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	200,000	$0.00	--

Holdings After Transaction: Ordinary Shares — 1,254,050 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Restricted share grant: 200,000 shares Grant price: $0.00 per share Post-transaction holdings: 1,254,050 shares +2 more

5 metrics

Restricted share grant 200,000 shares Grant of Ordinary Shares to CFO on March 26, 2026

Grant price $0.00 per share Price per restricted Ordinary Share granted to CFO

Post-transaction holdings 1,254,050 shares Ordinary Shares directly held by CFO after grant

Vesting period 2 years Restricted shares vest in equal quarterly installments

Vesting start date March 26, 2026 Grant date from which quarterly vesting begins

Key Terms

restricted shares, vest in equal quarterly installments, grant date, grant, award, or other acquisition

4 terms

restricted shares financial

"The restricted shares vest in equal quarterly installments over a two-year period"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

vest in equal quarterly installments financial

"The restricted shares vest in equal quarterly installments over a two-year period"

grant date financial

"commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eisenberg Or

(Last) (First) (Middle)

C/O NEUROSENSE THERAPEUTICS LTD.

11 HAMENOFIM STREET, BUILDING B

(Street)

HERZLIYA 4672562

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroSense Therapeutics Ltd. [ NRSN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/26/2026		A		200,000(1)	A	$0	1,254,050	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

	/s/ Or Eisenberg	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did NeuroSense Therapeutics (NRSN) disclose in this Form 4 filing?

NeuroSense Therapeutics reported that CFO Eisenberg Or received a grant of 200,000 restricted Ordinary Shares at $0.00 per share. These shares are part of his equity compensation and vest over time, rather than being purchased in the open market.

How many NeuroSense (NRSN) shares does the CFO hold after this grant?

After the grant, CFO Eisenberg Or directly holds 1,254,050 Ordinary Shares of NeuroSense Therapeutics. This figure includes the newly granted 200,000 restricted shares, which will vest over a two-year period starting on March 26, 2026, subject to continued service.

What are the vesting terms for the 200,000 restricted NeuroSense shares?

The 200,000 restricted Ordinary Shares granted to the CFO vest in equal quarterly installments over a two-year period. Vesting begins on the grant date of March 26, 2026 and requires his continued service with NeuroSense on each vesting date.

Did the NeuroSense (NRSN) CFO buy or sell shares in this Form 4?

The Form 4 shows an acquisition by grant, not a market purchase or sale. CFO Eisenberg Or received 200,000 restricted Ordinary Shares at $0.00 per share as a grant, award, or other acquisition rather than an open-market transaction.

Is this NeuroSense Form 4 transaction a routine compensation grant?

Yes. The transaction is coded as a grant, award, or other acquisition of 200,000 restricted Ordinary Shares for the CFO. The shares vest quarterly over two years starting March 26, 2026, a pattern typical of equity-based executive compensation tied to continued service.

Are there any derivative securities involved in this NeuroSense Form 4?

No derivative securities are listed in this Form 4. The filing reports only a non-derivative grant of 200,000 restricted Ordinary Shares to the CFO, with vesting in equal quarterly installments over two years from March 26, 2026, subject to continued service.